New Treatments in Chronic Liver Disease

MAIN CONFERENCE: MARCH 20-21, 2021
Pre-Conference: March 19, 2021
San Diego Mission Bay Resort • San Diego, California
Course Overview

This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials and real world data using oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

In 2017, the World Health Organization released the Global Hepatitis Report outlining the goals of viral eradication by 2030. This year we have invited Dr. John Ward, MD who is Head of the Viral Hepatitis Branch of the CDC to update the progress of the United States in accomplishing these goals. Details of antiviral therapies will be discussed during panel discussions.

New treatments which have been reported for both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) will be discussed by Dr. Kris Kowdley from the Swedish Liver Center in Seattle, WA. We also have invited Dr. Constantine J. Karvellas, Assistant Professor, Division of Gastroenterology, Department of Critical Care Medicine at the University of Alberta to act as our William S. Haubrich Memorial Lecturer on the topic of Acute Liver Failure. The course will also review alcoholic liver disease and NASH, which have now surpassed chronic hepatitis C as the leading indications for liver transplantation in the United States. The first FDA-approved therapy for NASH is anticipated in 2020 and the data supporting this FDA submission will be updated as well as the latest abstracts from AASLD 2020 on NASH. We have also invited a world-recognized expert on alcoholic liver disease to update our knowledge of the topic this year. Our conference will include a lecture on diet and exercise as management and prevention of obesity and fatty liver disease this year. We will also include a lecture on diagnosis and management of benign lesions of the liver given by an expert on this subject. And lastly, there will be a lecture devoted to the use of systemic therapies for hepatocellular carcinoma as there five approved drugs in the United States.

Although hepatitis B treatments have not changed, we now have more mature data available on long-term HBsAg loss and clinical outcomes. The addition of immune-mediated therapies for HBV with the goal of curing the disease will also be included in this year’s program. New therapies for NAFLD and NASH are in development and important new data showing positive results in NASH will be presented at this meeting, including the first results of a phase 3 global treatment trial. The explosive growth of NASH in the United States has created a significant need for effective drug therapy. A number of new systemic therapies for HCC that have been approved in the last two years will also be discussed. In addition, the course will provide updates on management of hepatic encephalopathy, hyponatremia, thrombocytopenia, and complications in the transplant candidate.

Accreditation & Disclosure

Physicians

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Scripps Health designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Breakdown

Pre-Conference (Fri): 3.5
Main Conference (Sat-Sun): 10

ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please note: ABIM MOC points will be awarded to those who successfully complete the requirements outlined in the post-conference evaluation. Points earned will be reported to the ABIM approximately 60 days post conference. These points will not appear on your CME certificate from Scripps.

Board of Registered Nursing

For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit(s)™ issued by organizations accredited by the ACCME. For the purpose of re-licensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credit(s)™ as meeting continuing education requirements for license renewal. Nurses should check with their state’s Board of Registered Nursing regarding use of CME credit.

American Academy of Physician Assistants

PAs may claim a maximum of 13.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME Accreditation Standards for Commercial Support. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

Educational Objectives

After attending this live activity, participants should be able to:

- Identify the steps required to accomplish eradication of chronic viral hepatitis by 2030.
- Review current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions.
- Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals.
- Discuss diagnosis, management and treatment unusual hepatitis virus infections.
- Update the skills and management required for transplant hepatology.
- Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
- Describe the diagnosis and treatment of PBC and PSC.
- Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorders.
- Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia.
- Update the diagnosis and management benign masses in the liver.
- Discuss the rising burden of alcoholic liver disease in the United States.
- Discuss advances in treatment of acute liver failure.
Course Directors

Paul J. Pockros, MD, FACG
Director, Liver Disease Center
Scripps Clinic
Director of Clinical Research
Scripps Translational Science Institute
La Jolla, California

Catherine T. Frenette, MD, FAST, AGAF
Medical Director of Liver Transplantation
Scripps Center for Organ and Cell Transplantation
Director, Liver and Hepatocellular Cancer Program
Scripps MD Anderson Cancer Center
La Jolla, California

Conference Faculty

Timothy J. Davern, MD
Director, Acute Liver Failure Program
Division, General and Transplant Hepatology Department
San Francisco Center for Liver Disease
Sutter Health
San Francisco, California

Ken Fujioka, MD
Director, Nutrition and Metabolic Research Center
Scripps Clinic
La Jolla, California

Constantine J. Karvellas, MD, SM, FRCPC, FCCM
Associate Professor, Division of Gastroenterology
Department of Critical Care Medicine
Adjunct Professor, School of Public Health Sciences
University of Alberta
Alberta, Canada

Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD
Director, Liver Care Network and Organ Care Research
Clinical Professor, College of Medicine
Washington State University
Swedish Liver Center
Seattle, Washington

Suthat Liangpunsakul, MD
Professor of Medicine, Biochemistry and Molecular Biology
Indiana University School of Medicine
Indianapolis, Indiana

Yuki Rosenkoetter, PAC, MPAS
Division of Gastroenterology and Hepatology
Scripps Clinic
La Jolla, California

Sammy Saab, MD, MPH, AGAF, FAASLD, FACP
Adjunct Professor, Internal Medicine and Surgery
Head, Outcomes Research in Hepatology
University of California, Los Angeles
Los Angeles, California

Mitchell L Shiffman, MD
Director, Liver Institute of Virginia
Bon Secours Mercy Health
Richmond, Virginia

Norman L. Sussman, MD
Associate Professor of Medicine and Surgery
Division of Abdominal Transplantation
Michael E. DeBakey Department of Surgery
Baylor College of Medicine
Houston, Texas

Norah A. Terrault, MD, MPH
Visiting Professor of Medicine, Chief
Division of Gastrointestinal and Liver
Keck School of Medicine of USC
Los Angeles, California

John W. Ward, MD
Director, Viral Hepatitis Program
Center for Disease Control and Prevention
Atlanta, Georgia

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

A complete listing of disclosures associated with this program can be found on the conference website: www.scripps.org/Livercme and in the mobile conference app: www.grupio.com/Liver21

Pre-Conference Agenda

Friday, March 19, 2021

12:30 p.m. Registration
1 p.m. Welcome & Introduction
Paul J. Pockros, MD
1:10 p.m. Epidemiology and Diagnosis Staging of NAFLD
Paul J. Pockros, MD
1:40 p.m. Current Treatment Option Including Diet and Exercise
Catherine T. Frenette, MD
2:40 p.m. Break & View Exhibits
3 p.m. New Drug Developments for NASH
Paul J. Pockros, MD
4 p.m. Case Presentation, Discussion and Q&A
Yuki Rosenkoetter, PAC, MPAS
5 p.m. Adjourn
Saturday, March 20, 2021

7:30 a.m.  Registration, Breakfast & View Exhibits

8 a.m.  Welcome & Introduction
Paul J. Pockros, MD

ALCOHOL AND VIRAL HEPATITIS
Moderator: Paul J. Pockros, MD

8:15 a.m.  HCV Eradication
John W. Ward, MD

8:45 a.m.  Update on HBV Therapies
Mitchell L Shiffman, MD

9:15 a.m.  Rising Burden of Alcoholic Liver Disease
Suthat Liangpunsakul, MD

9:45 a.m.  Break & View Exhibits

10 a.m.  Unusual Hepatic Viruses
Timothy J. Davern, MD

10:45 a.m.  DEBATE
Patients with Alcoholic Hepatitis Should Undergo Liver Transplant as Primary Treatment

Pro: Suthat Liangpunsakul, MD
Con: Catherine T. Frenette, MD

11 a.m.  Panel Discussion
Timothy J. Davern, MD
Mitchell L Shiffman, MD
Suthat Liangpunsakul, MD
John W. Ward, MD

11:45 a.m.  Lunch & View Exhibits

NAFLD, NASH AND OTHER DISORDERS
Moderator: Catherine T. Frenette, MD

12:45 p.m.  The Latest on PBC and PSC
Kris V. Kowdley, MD

1:15 p.m.  Benign Masses Identified in the Liver by Imaging
Sammy Saab, MD, MPH

1:45 p.m.  Diet and Lifestyle Changes for Obesity and NAFLD
Ken Fujioka, MD

2:15 p.m.  Break & View Exhibits

2:30 p.m.  AASLD Update for NASH
Paul J. Pockros, MD

3 p.m.  DEBATE
Should I Biopsy? Diagnosis of NASH

Yes: Kris V. Kowdley, MD
No: Paul J. Pockros, MD

3:30 p.m.  Panel Discussion
Ken Fujioka, MD
Kris V. Kowdley, MD
Paul J. Pockros, MD
Sammy Saab, MD, MPH

4:30 p.m.  Adjourn

Sunday, March 21, 2021

7:30 a.m.  Breakfast & View Exhibits

ESLD, HCC AND LIVER TRANSPLANTATION
Moderator: Paul J. Pockros, MD

8 a.m.  What Does the Gastroenterologist Need to Know: Systemic Therapies for HCC
Catherine T. Frenette, MD

8:30 a.m.  WILLIAM S. HAUBRICH MEMORIAL LECTURE
Acute Liver Failure
Constantine J. Karvellas, MD

9 a.m.  Virtual HCC Tumor Board
Discussants:
Constantine J. Karvellas, MD
Catherine T. Frenette, MD
Norman L. Sussman, MD
Norah A. Terrault, MD

9:30 a.m.  Break & View Exhibits

10 a.m.  Medical Care of the Cirrhotic Patient
Norman L. Sussman, MD

10:30 a.m.  Post-Transplant Complications: What the Gastroenterology Community Needs to Know
Norah A. Terrault, MD

11 a.m.  Panel Discussion
Constantine J. Karvellas, MD
Catherine T. Frenette, MD
Norman L. Sussman
Norah A. Terrault, MD

11:30 a.m.  Final Adjournment

Topics, times and speakers are subject to change

Conference Highlights

- Half day pre-conference seminar reviewing the virology, genotypes and modes of infection of HCV
- Plenary talks from nationally recognized experts
- Presentations on hot topics, upcoming scientific developments, and current advances in chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease
- Networking opportunities among colleagues
- Conference app with access to course materials and recordings from the convenience of your mobile device or computer
Conference Fees

Space is limited so register early!

**Included:** Course tuition, breakfasts, breaks, lunch, internet access, and electronic course materials

**Not Included:** Travel costs, lodging, dinners, and parking

### MAIN CONFERENCE

<table>
<thead>
<tr>
<th></th>
<th>Through Jan 31</th>
<th>Feb 1 - Mar 15</th>
<th>On-site after Mar 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-conference Workshop</td>
<td>$100</td>
<td>$125</td>
<td>$150</td>
</tr>
<tr>
<td>Physicians (MD, DO)</td>
<td>$360</td>
<td>$385</td>
<td>$410</td>
</tr>
<tr>
<td>Non-Physicians (RN, PA, NP)</td>
<td>$290</td>
<td>$315</td>
<td>$340</td>
</tr>
<tr>
<td>Fellows, Residents, Students</td>
<td>$185</td>
<td>$210</td>
<td>$235</td>
</tr>
</tbody>
</table>

Register Online: [www.scripps.org/livercme](http://www.scripps.org/livercme)

**Attendance Policies**

**Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a $100 processing fee (MD, DO, RN, PA, NP) or a $50 processing fee (Fellow, Resident, Student), if your cancellation is received in writing no later than Monday, March 15, 2021. Attendee substitutions are allowed, but notification must be made in writing by Monday, March 15, 2021. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to “no shows.” Pre-conference workshop registration fees will be refunded in full until March 15, 2021.

**Guest Attendance Policy**

All conference activities, including meal functions, are exclusively reserved for paid conference attendees. Children and family members are not allowed in the conference areas. Badges provided at registration are required for entrance into all functions and will be strictly enforced.

**Scripps Conference Modification or Cancellation**

Scripps reserves the right to modify the course’s schedule or program as necessary. Scripps also reserves the right to cancel this conference, in which case a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of Scripps cancellation.

**Recording and Photography Clause**

Scripps reserves exclusive rights to record (audio and video) and/or photograph all conference proceedings for use in marketing materials, presentations and course content sales.
New Treatments in Chronic Liver Disease

Target Audience

- Hepatologists
- Gastroenterologists
- Infectious Disease Specialists
- Nurse Practitioners
- Physician Assistants
- Nurses
- Residents/Fellows